Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BCAX

Bicara Therapeutics Inc

Mar 20 • 04:00PM ET

18.41

-0.38 -2.02 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI XBI IWM VXF IWN IBB SCHA VTWO FESM VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.23	Insider Own	42.00%	Shs Outstand	54.61M	Perf Week	-4.06%
Market Cap	1.17B	Forward P/E	-	EPS next Y	-3.03	Insider Trans	-0.44%	Shs Float	36.75M	Perf Month	19.39%
Enterprise Value	878.32M	PEG	-	EPS next Q	-0.67	Inst Own	76.87%	Short Float	25.22%	Perf Quarter	2.39%
Income	-121.52M	P/S	-	EPS this Y	37.91%	Inst Trans	12.40%	Short Ratio	19.01	Perf Half Y	66.46%
Sales	0.00M	P/B	2.50	EPS next Y	-20.49%	ROA	-25.61%	Short Interest	9.27M	Perf YTD	9.39%
Book/sh	7.38	P/C	4.02	EPS next 5Y	8.12%	ROE	-26.64%	52W High	20.25 -9.09%	Perf Year	40.64%
Cash/sh	4.58	P/FCF	-	EPS past 3/5Y	-34.00% -	ROIC	-30.10%	52W Low	7.80 136.03%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.69% 6.70%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-103.95%	Oper. Margin	-	ATR (14)	1.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.14	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.76	Recom	1.46
Dividend Gr. 3/5Y	- -	Current Ratio	14.14	EPS Q/Q	-107.22%	SMA20	0.29%	Beta	-1.02	Target Price	29.27
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	7.95%	Rel Volume	2.44	Prev Close	18.79
Employees	55	LT Debt/Eq	0.00	Earnings	Nov 10 BMO	SMA200	26.40%	Avg Volume	487.65K	Price	18.41
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.82% -	Trades		Volume	1,190,899	Change	-2.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-26	Initiated	Citizens JMP	Mkt Perform	$31
Jan-08-26	Initiated	BTIG Research	Buy	$28
Dec-18-25	Initiated	Mizuho	Neutral	$18
Aug-19-25	Initiated	Piper Sandler	Overweight	$36
May-23-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$8
Apr-17-25	Initiated	Wells Fargo	Underweight	$8
Feb-06-25	Initiated	Wedbush	Outperform	$31
Dec-06-24	Initiated	H.C. Wainwright	Buy	$42
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$48
Oct-08-24	Initiated	TD Cowen	Buy
Oct-08-24	Initiated	Stifel	Buy	$47
Oct-08-24	Initiated	Morgan Stanley	Overweight	$35
Oct-08-24	Initiated	Cantor Fitzgerald	Overweight

Show Previous Ratings

Mar-06-26 05:47AM	Bicara Therapeutics Touts FICERA Data, Sets Pivotal FORTIFY Path at TD Cowen Conference (MarketBeat)
Mar-04-26 08:30AM	Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-26 04:01PM	Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Feb-24-26 11:13PM	Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +7.82%
04:01PM	Bicara Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
11:10AM	Loading…
Feb-23-26 11:10AM	Bicara Therapeutics Shares New FICERA Data, Eyes Less Frequent Dosing in Head & Neck Cancer (MarketBeat) +5.94%
08:30AM	Bicara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 04:30PM	Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen (GlobeNewswire) +6.42%
Feb-05-26 08:30AM	Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.76%
Jan-13-26 01:08AM	Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial (MarketBeat)
Jan-12-26 08:00AM	Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook (GlobeNewswire)
Dec-15-25 08:00AM	Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12 (GlobeNewswire)
Dec-06-25 08:00AM	Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 (GlobeNewswire)
Dec-01-25 07:00AM	Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 (GlobeNewswire) -6.63%
Nov-10-25 07:30AM	Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
08:30AM	Loading…
Oct-27-25 08:30AM	Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology (PR Newswire)
Oct-13-25 07:30AM	Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC (GlobeNewswire)
Aug-27-25 04:01PM	Bicara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 09:55AM	Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect? (Zacks)
Aug-12-25 07:30AM	Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jun-11-25 04:05PM	Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors (GlobeNewswire) -5.56%
Jun-03-25 04:01PM	Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +11.21%
Jun-01-25 01:12PM	Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 (GlobeNewswire)
May-29-25 06:54AM	ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer (Clinical Trials Arena)
May-27-25 01:59PM	Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update (Insider Monkey) +7.66%
May-26-25 09:14AM	Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients (Insider Monkey)
May-23-25 10:15AM	Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics (Investor's Business Daily) -40.80%
May-22-25 05:00PM	Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting (GlobeNewswire) +7.33%
May-13-25 07:30AM	Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -8.10%
Apr-28-25 04:01PM	Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 (GlobeNewswire)
10:00AM	Loading…
Apr-23-25 10:00AM	Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +12.23%
Apr-19-25 06:22AM	Bicara: Innovative Precision Tumor Targeting (Seeking Alpha)
Mar-27-25 07:30AM	Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-25 04:45PM	Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 (GlobeNewswire) -5.58%
Feb-24-25 04:01PM	Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-11-25 04:01PM	Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jan-27-25 08:00AM	Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-08-25 10:16AM	Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia (Clinical Trials Arena)
Nov-12-24 07:30AM	Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.30%
Nov-11-24 04:01PM	Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Oct-08-24 10:44AM	MBX Biosciences earns Buy rating at three investment firms (Investing.com) -7.77%
Sep-23-24 07:05PM	RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares (GuruFocus.com)
Sep-19-24 01:13AM	TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-18-24 03:01PM	FMR LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-17-24 09:13AM	Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity (Pharmaceutical Technology) +6.53%
Sep-16-24 04:01PM	Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.54%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 09:15PM	Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
07:02PM	Three biotechs raise $700M in rare burst of IPO activity (BioPharma Dive)

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company's bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mazumdar Claire	Chief Executive Officer	Mar 19 '26	Option Exercise	3.79	6,905	26,169	346,297	Mar 20 05:02 PM
Mazumdar Claire	Chief Executive Officer	Mar 18 '26	Option Exercise	3.79	6,499	24,630	345,891	Mar 20 05:02 PM
Mazumdar Claire	Chief Executive Officer	Mar 20 '26	Option Exercise	3.79	1,596	6,049	340,988	Mar 20 05:02 PM
Mazumdar Claire	Chief Executive Officer	Mar 19 '26	Sale	18.78	6,905	129,705	339,392	Mar 20 05:02 PM
Mazumdar Claire	Chief Executive Officer	Mar 18 '26	Sale	18.84	6,499	122,415	339,392	Mar 20 05:02 PM
Mazumdar Claire	Chief Executive Officer	Mar 20 '26	Sale	18.95	1,596	30,246	339,392	Mar 20 05:02 PM
Mazumdar Claire	Officer	Mar 20 '26	Proposed Sale	18.95	1,596	30,246		Mar 20 04:08 PM
Mazumdar Claire	Officer	Mar 19 '26	Proposed Sale	18.78	6,905	129,705		Mar 19 04:27 PM
Mazumdar Claire	Officer	Mar 18 '26	Proposed Sale	19.19	6,499	124,716		Mar 18 04:26 PM
Cohlhepp Ryan	President and COO	Mar 16 '26	Option Exercise	3.79	8,000	30,318	213,141	Mar 17 05:36 PM
Cohlhepp Ryan	President and COO	Mar 16 '26	Sale	19.66	12,500	245,714	200,641	Mar 17 05:36 PM
Cohlhepp Ryan	Officer	Mar 16 '26	Proposed Sale	19.34	12,500	241,750		Mar 16 04:03 PM
Mazumdar Claire	Chief Executive Officer	Mar 09 '26	Option Exercise	3.79	36,766	139,336	376,158	Mar 11 04:47 PM
Mazumdar Claire	Chief Executive Officer	Mar 09 '26	Sale	19.17	36,766	704,657	339,392	Mar 11 04:47 PM
Mazumdar Claire	Officer	Mar 09 '26	Proposed Sale	19.17	36,766	704,657		Mar 09 04:06 PM
Mazumdar Claire	Chief Executive Officer	Mar 06 '26	Option Exercise	3.79	3,817	14,466	343,209	Mar 06 07:27 PM
Mazumdar Claire	Chief Executive Officer	Mar 04 '26	Option Exercise	3.79	2,631	9,971	342,023	Mar 06 07:27 PM
Mazumdar Claire	Chief Executive Officer	Mar 05 '26	Option Exercise	3.79	1,786	6,769	341,178	Mar 06 07:27 PM
Mazumdar Claire	Chief Executive Officer	Mar 06 '26	Sale	18.75	3,817	71,572	339,392	Mar 06 07:27 PM
Mazumdar Claire	Chief Executive Officer	Mar 04 '26	Sale	18.73	2,631	49,289	339,392	Mar 06 07:27 PM
Mazumdar Claire	Chief Executive Officer	Mar 05 '26	Sale	18.74	1,786	33,464	339,392	Mar 06 07:27 PM
Mazumdar Claire	Officer	Mar 06 '26	Proposed Sale	19.80	3,817	75,572		Mar 06 04:01 PM
Cohlhepp Ryan	President and COO	Mar 03 '26	Option Exercise	3.79	12,892	48,858	222,533	Mar 05 07:10 PM
Cohlhepp Ryan	President and COO	Mar 03 '26	Sale	18.16	17,392	315,893	205,141	Mar 05 07:10 PM
Hyep Ivan	Chief Financial Officer	Mar 03 '26	Option Exercise	3.79	13,555	51,371	158,910	Mar 05 07:08 PM
Hyep Ivan	Chief Financial Officer	Mar 04 '26	Option Exercise	3.79	2,963	11,229	148,318	Mar 05 07:08 PM
Hyep Ivan	Chief Financial Officer	Mar 03 '26	Sale	18.22	13,555	246,910	145,355	Mar 05 07:08 PM
Hyep Ivan	Chief Financial Officer	Mar 04 '26	Sale	18.25	2,963	54,062	145,355	Mar 05 07:08 PM
Raben David	Chief Medical Officer	Mar 04 '26	Option Exercise	3.79	16,300	61,774	71,586	Mar 05 07:06 PM
Raben David	Chief Medical Officer	Mar 03 '26	Option Exercise	3.79	200	758	55,486	Mar 05 07:06 PM
Raben David	Chief Medical Officer	Mar 04 '26	Sale	18.52	16,300	301,920	55,286	Mar 05 07:06 PM
Raben David	Chief Medical Officer	Mar 03 '26	Sale	18.45	200	3,690	55,286	Mar 05 07:06 PM
Mazumdar Claire	Officer	Mar 05 '26	Proposed Sale	18.74	1,786	33,464		Mar 05 04:04 PM
Hyep Ivan	Officer	Mar 04 '26	Proposed Sale	18.25	2,963	54,062		Mar 04 04:32 PM
Mazumdar Claire	Officer	Mar 04 '26	Proposed Sale	18.73	2,631	49,289		Mar 04 04:31 PM
Raben David	Officer	Mar 04 '26	Proposed Sale	18.52	16,300	301,920		Mar 04 04:21 PM
Hyep Ivan	Officer	Mar 03 '26	Proposed Sale	18.22	13,555	246,910		Mar 03 04:48 PM
Raben David	Officer	Mar 03 '26	Proposed Sale	18.45	200	3,690		Mar 03 04:11 PM
Cohlhepp Ryan	Officer	Mar 03 '26	Proposed Sale	18.16	17,392	315,893		Mar 03 04:09 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 26 '26	Buy	16.00	300,000	4,800,000	4,603,418	Mar 02 04:22 PM
Cohlhepp Ryan	President and COO	Feb 25 '26	Option Exercise	3.79	3,108	11,779	213,272	Feb 27 04:13 PM
Cohlhepp Ryan	President and COO	Feb 25 '26	Sale	18.04	3,631	65,501	209,641	Feb 27 04:13 PM
Cohlhepp Ryan	Officer	Feb 25 '26	Proposed Sale	18.04	3,631	65,501		Feb 25 04:03 PM
Cohlhepp Ryan	President and COO	Jan 22 '26	Sale	18.10	3,828	69,296	210,164	Jan 26 04:34 PM
Hyep Ivan	Chief Financial Officer	Jan 22 '26	Option Exercise	3.79	1,882	7,132	147,237	Jan 26 04:33 PM
Hyep Ivan	Chief Financial Officer	Jan 22 '26	Sale	18.15	1,882	34,162	145,355	Jan 26 04:33 PM
Cohlhepp Ryan	Officer	Jan 22 '26	Proposed Sale	16.97	3,828	64,961		Jan 22 04:07 PM
Hyep Ivan	Officer	Jan 22 '26	Proposed Sale	18.15	1,882	34,158		Jan 22 04:03 PM
Cohlhepp Ryan	President and COO	Jan 15 '26	Sale	18.02	149	2,685	213,992	Jan 20 04:52 PM
Cohlhepp Ryan	Officer	Jan 15 '26	Proposed Sale	18.02	149	2,685		Jan 15 04:03 PM
Cohlhepp Ryan	President and COO	Dec 26 '25	Option Exercise	4.44	25,000	110,922	214,141	Dec 29 05:18 PM
Raben David	Chief Medical Officer	Dec 26 '25	Option Exercise	3.79	19,789	74,996	55,286	Dec 29 05:10 PM
Hyep Ivan	Chief Financial Officer	Dec 22 '25	Option Exercise	3.79	9,200	34,866	154,555	Dec 23 04:02 PM
Hyep Ivan	Chief Financial Officer	Dec 22 '25	Sale	18.31	9,200	168,492	145,355	Dec 23 04:02 PM
Hyep Ivan	Officer	Dec 22 '25	Proposed Sale	17.87	9,200	164,404		Dec 22 04:08 PM
Mazumdar Claire	Chief Executive Officer	Dec 16 '25	Option Exercise	5.45	29,500	160,884	339,392	Dec 18 06:02 PM
Cohlhepp Ryan	President and COO	Dec 15 '25	Option Exercise	3.79	8,000	30,318	201,641	Dec 16 04:52 PM
Cohlhepp Ryan	President and COO	Dec 15 '25	Sale	18.68	12,500	233,548	189,141	Dec 16 04:52 PM
Cohlhepp Ryan	Officer	Dec 15 '25	Proposed Sale	18.70	12,500	233,750		Dec 15 04:04 PM
Hyep Ivan	Chief Financial Officer	Nov 24 '25	Option Exercise	3.79	17,795	67,439	163,150	Nov 25 06:42 PM
Hyep Ivan	Chief Financial Officer	Nov 21 '25	Option Exercise	3.79	605	2,293	145,960	Nov 25 06:42 PM
Hyep Ivan	Chief Financial Officer	Nov 24 '25	Sale	18.55	17,795	330,094	145,355	Nov 25 06:42 PM
Hyep Ivan	Chief Financial Officer	Nov 21 '25	Sale	18.15	605	10,981	145,355	Nov 25 06:42 PM
Cohlhepp Ryan	President and COO	Nov 21 '25	Option Exercise	3.79	8,000	30,318	206,141	Nov 25 06:41 PM
Cohlhepp Ryan	President and COO	Nov 21 '25	Sale	18.05	12,500	225,588	193,641	Nov 25 06:41 PM
Mazumdar Claire	Chief Executive Officer	Nov 24 '25	Option Exercise	3.79	41,163	156,000	351,055	Nov 25 06:40 PM
Mazumdar Claire	Chief Executive Officer	Nov 24 '25	Sale	18.86	41,163	776,429	309,892	Nov 25 06:40 PM
Raben David	Chief Medical Officer	Nov 24 '25	Option Exercise	3.79	5,500	20,844	40,997	Nov 25 06:39 PM
Raben David	Chief Medical Officer	Nov 25 '25	Option Exercise	3.79	5,500	20,844	40,091	Nov 25 06:39 PM
Raben David	Chief Medical Officer	Nov 25 '25	Sale	18.84	5,500	103,633	35,497	Nov 25 06:39 PM
Raben David	Chief Medical Officer	Nov 24 '25	Sale	18.45	5,500	101,475	35,497	Nov 25 06:39 PM
Raben David	Officer	Nov 25 '25	Proposed Sale	18.84	5,500	103,633		Nov 25 04:29 PM
Mazumdar Claire	Officer	Nov 24 '25	Proposed Sale	18.86	41,163	776,429		Nov 24 04:24 PM
Hyep Ivan	Officer	Nov 24 '25	Proposed Sale	18.55	17,795	330,094		Nov 24 04:10 PM
Raben David	Officer	Nov 24 '25	Proposed Sale	18.45	5,500	101,475		Nov 24 04:09 PM
Hyep Ivan	Officer	Nov 21 '25	Proposed Sale	18.15	605	10,981		Nov 21 04:33 PM
Cohlhepp Ryan	Officer	Nov 21 '25	Proposed Sale	18.05	12,500	225,588		Nov 21 04:32 PM
Cohlhepp Ryan	President and COO	Oct 15 '25	Option Exercise	3.79	8,000	30,318	210,641	Oct 16 04:41 PM
Cohlhepp Ryan	President and COO	Oct 15 '25	Sale	18.16	12,500	226,942	198,141	Oct 16 04:41 PM
Mazumdar Claire	Officer	Oct 16 '25	Proposed Sale	18.83	24,103	453,761		Oct 16 04:13 PM
Mazumdar Claire	Chief Executive Officer	Oct 15 '25	Option Exercise	3.79	13,289	50,363	323,181	Oct 15 06:00 PM
Mazumdar Claire	Chief Executive Officer	Oct 13 '25	Option Exercise	3.79	11,445	43,374	321,337	Oct 15 06:00 PM
Mazumdar Claire	Chief Executive Officer	Oct 15 '25	Sale	18.84	13,289	250,391	309,892	Oct 15 06:00 PM
Mazumdar Claire	Chief Executive Officer	Oct 13 '25	Sale	18.92	11,445	216,545	309,892	Oct 15 06:00 PM
Cohlhepp Ryan	Officer	Oct 15 '25	Proposed Sale	18.13	12,500	226,601		Oct 15 04:20 PM
Mazumdar Claire	Officer	Oct 15 '25	Proposed Sale	18.84	13,289	250,391		Oct 15 04:18 PM
Mazumdar Claire	Officer	Oct 13 '25	Proposed Sale	18.92	11,445	216,545		Oct 14 09:05 AM
Raben David	Chief Medical Officer	Oct 09 '25	Option Exercise	3.79	22,000	83,376	57,497	Oct 10 05:23 PM
Raben David	Chief Medical Officer	Oct 09 '25	Sale	18.45	22,000	405,900	35,497	Oct 10 05:23 PM
Hyep Ivan	Chief Financial Officer	Oct 09 '25	Option Exercise	3.79	6,415	24,312	151,770	Oct 10 05:22 PM
Hyep Ivan	Chief Financial Officer	Oct 09 '25	Sale	18.23	6,415	116,931	145,355	Oct 10 05:22 PM
Hyep Ivan	Officer	Oct 09 '25	Proposed Sale	17.89	6,415	114,764		Oct 09 04:31 PM
Raben David	Officer	Oct 09 '25	Proposed Sale	18.45	22,000	405,900		Oct 09 04:08 PM
Hyep Ivan	Chief Financial Officer	Oct 07 '25	Option Exercise	3.79	18,244	69,141	163,599	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 06 '25	Option Exercise	3.79	6,514	24,687	151,869	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 08 '25	Option Exercise	3.79	5,627	21,325	150,982	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 07 '25	Sale	18.22	18,244	332,386	145,355	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 06 '25	Sale	18.17	6,514	118,356	145,355	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 08 '25	Sale	18.21	5,627	102,456	145,355	Oct 08 05:33 PM
Cohlhepp Ryan	President and COO	Oct 06 '25	Option Exercise	3.79	24,000	90,955	245,141	Oct 08 05:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCAX

Bicara Therapeutics Inc

Upgrade your FINVIZ experience